Nonviral gene transfer to murine liver in vivo is enhanced by exposure to high‐amplitude, 1‐MHz ultrasound with Optison■.

2006 ◽  
Vol 119 (5) ◽  
pp. 3406-3406
Author(s):  
Andrew A. Brayman ◽  
Zhenping Shen ◽  
Liping Chen ◽  
Carol Miao
Keyword(s):  
Gene Transfer ◽  
High Amplitude ◽  
Nonviral Gene Transfer ◽  
Murine Liver

scholarly journals Nonviral gene transfer to skeletal, smooth, and cardiac muscle in living animals

2005 ◽  
Vol 289 (2) ◽  
pp. C233-C245 ◽  
Author(s):  
David A. Dean
Keyword(s):  
Gene Transfer ◽  
Cardiac Muscle ◽  
Muscle Physiology ◽  
Gene Products ◽  
Nonviral Gene Transfer ◽  
The Past ◽  
Recent Developments ◽  
Muscle Types ◽  
In Vivo Gene Transfer

The study of muscle physiology has undergone many changes over the past 25 years and has moved from purely physiological studies to those intimately intertwined with molecular and cell biological questions. To ask these questions, it is necessary to be able to transfer genetic reagents to cells both in culture and, ultimately, in living animals. Over the past 10 years, a number of different chemical and physical approaches have been developed to transfect living skeletal, smooth, and cardiac muscle systems with varying success and efficiency. This review provides a survey of these methods and describes some more recent developments in the field of in vivo gene transfer to these various muscle types. Both gene delivery for overexpression of desired gene products and delivery of nucleic acids for downregulation of specific genes and their products are discussed to aid the physiologist, cell biologist, and molecular biologist in their studies on whole animal biology.

Nuclear‐targeted chimeric vector enhancing nonviral gene transfer into skeletal muscle of Fabry mice in vivo

2008 ◽  
Vol 22 (6) ◽  
pp. 2097-2107 ◽  
Author(s):  
Matthieu D. Lavigne ◽  
Laura Yates ◽  
Peter Coxhead ◽  
Dariusz C. Górecki
Keyword(s):  
Skeletal Muscle ◽  
Gene Transfer ◽  
Nonviral Gene Transfer

scholarly journals Optimization of Nonviral Gene Transfer of Vascular Smooth Muscle Cells in Vitro and in Vivo

2000 ◽  
Vol 1 (4) ◽  
pp. 366-375 ◽  
Author(s):  
Sorin Armeanu ◽  
Jaroslav Pelisek ◽  
Eberhard Krausz ◽  
Alexandra Fuchs ◽  
Detlef Groth ◽  
...  
Keyword(s):  
Smooth Muscle ◽  
Gene Transfer ◽  
Vascular Smooth Muscle ◽  
Smooth Muscle Cells ◽  
Vascular Smooth Muscle Cells ◽  
Muscle Cells ◽  
Nonviral Gene Transfer

Nonviral gene delivery: techniques and implications for molecular medicine

2003 ◽  
Vol 5 (22) ◽  
pp. 1-15 ◽  
Author(s):  
Alan L. Parker ◽  
Christopher Newman ◽  
Simon Briggs ◽  
Leonard Seymour ◽  
Paul J. Sheridan
Keyword(s):  
Gene Transfer ◽  
Viral Vectors ◽  
Nonviral Gene Delivery ◽  
Molecular Medicine ◽  
Viral Gene ◽  
Nonviral Vector ◽  
Nonviral Gene Transfer ◽  
Novel Strategy ◽  
The Many

Medical research continues to illuminate the origins of many human diseases. Gene therapy has been widely proposed as a novel strategy by which this knowledge can be used to deliver new and improved therapies. Viral gene transfer is relatively efficient but there are concerns relating to the use of viral vectors in humans. Conversely, nonviral vectors appear safe but inefficient. Therefore, the development of an efficient nonviral vector remains a highly desirable goal. This review focuses on the numerous challenges preventing efficient nonviral gene transfer in vivo and discusses the many technologies that have been adopted to overcome these problems.

1860: Generation of Fluorescent Sperm by Use of in VIVO Gene Transfer to Hamster Testes

2007 ◽  
Vol 177 (4S) ◽  
pp. 617-618
Author(s):  
Hiraki Kubota ◽  
Kevin Coward ◽  
Olivia Hibbitt ◽  
Nilendran Prathalingam ◽  
William Holt ◽  
...  
Keyword(s):  
Gene Transfer ◽  
In Vivo Gene Transfer

scholarly journals An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer

Blood ◽  
1992 ◽  
Vol 79 (10) ◽  
pp. 2694-2700 ◽  
Author(s):  
DR Rill ◽  
RC Moen ◽  
M Buschle ◽  
C Bartholomew ◽  
NK Foreman ◽  
...  
Keyword(s):  
Gene Transfer ◽  
Marrow Transplantation ◽  
Residual Disease ◽  
Marker Gene ◽  
Autologous Bone Marrow Transplantation ◽  
Autologous Bone Marrow ◽  
Disease Recurrence ◽  
Malignant Cells

Abstract Autologous bone marrow transplantation (ABMT) is widely used as treatment for malignant disease. Although the major cause of treatment failure is relapse, it is unknown if this arises entirely because of residual disease in the patient or whether contaminating cells in the rescuing marrow contribute. Attempts to purge marrow of its putative residual malignant cells may delay hematopoietic reconstitution and are of uncertain efficacy. We now describe how retrovirus-mediated gene transfer may be used to elucidate the source of relapse after ABMT for acute myeloid leukemia and to evaluate the efficacy of purging. Clonogenic myeloid leukemic blast cells in patient marrow can be transduced with the NeoR gene-containing helper-free retrovirus, LNL6, with an efficacy of 0% to 23.5% (mean, 10.5%). Transduced colonies grow in selective media and the presence of the marker gene can be confirmed in individual malignant colonies by polymerase chain reaction. If such malignant cells remain in harvested “remission” marrow, they will therefore be marked after exposure to LNL6. Detection of the marker gene in the malignant cells present at any later relapse would be firm evidence that residual disease contributed to disease recurrence, and would permit rapid subsequent evaluation of purging techniques. The technique also marks normal marrow progenitors from patients with acute myeloblastic leukemia. These colony-forming cells can be detected in long-term marrow cultures at a frequency of 1% to 18% for up to 10 weeks after exposure to the vector. Animal models and analysis of probability tables both suggest that these levels of marking in vitro are sufficient to provide information about the mechanisms of relapse and the biology of marrow regeneration in vivo. These preclinical data form part of the basis for current clinical studies of gene transfer into marrow before ABMT.

scholarly journals Gene transfer of multidrug resistance into a factor-dependent human hematopoietic progenitor cell line: in vivo model for genetically transferred chemoprotection

Blood ◽  
1996 ◽  
Vol 87 (7) ◽  
pp. 2723-2731 ◽  
Author(s):  
P Schwarzenberger ◽  
S Spence ◽  
N Lohrey ◽  
T Kmiecik ◽  
DL Longo ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Multidrug Resistance ◽  
Gene Transfer ◽  
Hematopoietic Progenitor Cells ◽  
Mdr1 Gene ◽  
In Vivo Model ◽  
Hematopoietic Progenitor ◽  
Human Dna

To develop a rapid preclinical in vivo model to study gene transfer into human hematopoietic progenitor cells, MO-7e cells (CD-34+, c-kit+) were infected with multidrug resistance (MDR1)-containing retroviruses and then transplanted into nonobese diabetic severe combined immunodeficient mice (NOD SCID). MO-7e cells infected with a retrovirus encoding the human MDR1 cDNA showed integration, transcription, and expression of the transfered MDR1 gene. This resulted in a 20-fold increase in the resistance of MO-7e cells to paclitaxel in vitro. The expression of the MDR1 gene product was stable over a 6-month period in vitro without selection in colchicine. MO-7e and MDR1-infected MO-7e cells were transplanted into NOD SCID mice to determine whether MDR1 could confer drug resistance in vivo. A sensitive polymerase chain reaction method specific for human sequences was developed to quantitate the level of human cell engraftment in NOD SCID bone marrow (BM) cells. The percentage of human DNA in BM cells from MO-7e- transplanted mice was 10.9% and decreased to 0.7% in mice treated with paclitaxel. The percentage of human DNA in infected-MO-7e transplanted mice was 7.6% and that level was unchanged in mice treated with paclitaxel. These results show that expression of the MDR1 gene in human hematopoietic progenitor cells can confer functional drug resistance in an in vivo model.

Sign in / Sign up

Export Citation Format

Share Document